1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > REGULATORY
REGULATORY
- 93 Health Damages Reported for Temcell in Japan: October-March
July 24, 2023
- Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
July 24, 2023
- Japan Might See COVID-19 Spike in Summer: Top Govt Spokesman
July 24, 2023
- Tadayuki Mizutani Tapped as MHLW Director for Pharma Industry Promotion
July 24, 2023
- Phase Out or Scrap Inflation Mitigation Measures: CEFP Members
July 21, 2023
- Label Revisions Ordered for Xocova, Mounjaro to Add New ADR Risks
July 21, 2023
- LDP Policy Panel OKs FY2024 Budget Guidelines, Social Security Wording Unchanged
July 20, 2023
- Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
July 18, 2023
- Perjeta/Herceptin SC Combo Up for MHLW Panel Review on July 31
July 18, 2023
- Reflect Price and Wage Hikes in FY2024 Budget Guidelines, Lawmakers Urge
July 18, 2023
- Relief Claims OK’ed for 6 More Deaths Possibly Tied to COVID Jabs
July 18, 2023
- Japan Weighs Adoption of EMA Approach for Nitrosamine Impurities Risk Assessment
July 14, 2023
- Japan Govt to Stockpile Xofluza for 1.44 Million People
July 14, 2023
- Chuikyo OKs CEA Organization’s Reform Directions for FY2024
July 13, 2023
- Chuikyo Reps Want More Data from Industry to Review Launch Premiums
July 13, 2023
- Chuikyo Discusses Price Maintenance Premium, Focus Is on Company Criteria
July 13, 2023
- Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
- MHLW Certifies Antibiotics Supply Assurance Plans from Meiji, Fujifilm, Otsuka
July 12, 2023
- MHLW Panel OKs 172 More Health Damage Claims for COVID Vaccines
July 12, 2023
- MHLW Presents Plan to Expand Orphan Drug Designation by Clarifying Requirements
July 11, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…